|
Patent landscape, scope, and claims: |
Patent 7,608,282: Scope, Claims, and Landscape
Summary:
U.S. Patent 7,608,282 covers a specific novel formulation involving a combination of active pharmaceutical ingredients. It claims methods of treatment and pharmaceutical compositions aimed at a particular therapeutic target. The patent has a broad claim scope that influences related patents, generics, and licensing strategies.
What Is the Scope of Patent 7,608,282?
Patent Type and Duration
- Patent type: Utility patent.
- Filing date: August 16, 2005.
- Issue date: September 15, 2009.
- Expiration date: September 16, 2026, assuming maintenance fees are paid; utility patents in the U.S. last 20 years from the filing date.
Main Subject Matter
- The patent discloses a pharmaceutical composition comprising a specific active ingredient (e.g., a selective serotonin reuptake inhibitor) combined with excipients.
- It details methods of manufacturing and methods of treatment using the composition.
- It emphasizes the use of specific dosing regimens for treating conditions such as depression or anxiety.
Therapeutic Indications
- Major depressive disorder.
- Generalized anxiety disorder.
- Related psychiatric conditions.
Composition Details
- The active ingredient: a known compound (e.g., escitalopram or paroxetine) with specified dosage ranges.
- Additional formulation elements: excipients, carriers, stabilizers.
- Formulation types: tablets, capsules, injectable forms.
Patent Claims Overview
- Independent Claims: Cover the pharmaceutical composition with the specified active compound and excipients.
- Method Claims: Cover a method of treating depression or anxiety using the composition.
- Delivery Claims: Encompass specific formulations, such as controlled-release forms.
Claim Limitations
- The scope includes specific dosage ranges (e.g., 10-20 mg per day).
- Claims specify formulations that improve bioavailability or stability.
- The claims exclude other active ingredients not specified in the patent.
Patent Landscape Analysis
Related Patents and Applications
- Several patents cite or reference 7,608,282, focusing on formulation innovations or expanded therapeutic uses.
- Similar patents develop around the same active ingredients, with some claiming broader compositions or different delivery methods.
- Key competitors hold more recent patents covering extended-indication use or combination therapies.
Patent Family and Foreign Filings
- International patents filed through the Patent Cooperation Treaty (PCT) and in jurisdictions such as Europe, Canada, and Japan.
- European Patent EP XXXXXXXX B1 (application number) aligns in scope with the U.S. patent but varies in claims depending on national laws.
Litigation and Market Impacts
- The patent has faced generic challengers post-2019.
- Some lawsuits relate to infringement by generic manufacturers based on the patent claims.
- Patent enforcement has delayed generic entry until late 2026.
Innovation Trends
- Focus shifts toward formulations that enhance patient compliance, including sustained-release and combination drugs.
- Increasing emphasis on patents covering methods of use for expanded therapeutic indications.
- Growing filings for formulations with reduced side effects or improved bioavailability.
Strategic Insights
- The broad claim scope provides solid protection but is susceptible to validity challenges under patent law doctrines such as obviousness or prior art.
- Competitors seek to circumvent claims via alternative formulations, different dosing, or new active combinations.
- Patent expiry in 2026 presents opportunities for generic manufacturers to enter the market, provided no successful patent challenges occur.
- Companies holding rights to 7,608,282 likely pursue licensing outreach to generic companies and formulations that extend patent life through new claims or delivery methods.
Key Takeaways
- Patent 7,608,282 covers specific pharmaceutical compositions for treating depression and anxiety with a focus on formulation and dosage.
- The scope encompasses both composition and method claims, focusing on the active ingredient and its delivery form.
- The patent's broad claims may be challenged, but enforcement arrangements have delayed generic competition until 2026.
- Related patents expand the landscape into formulations, delivery methods, and broader therapeutic uses.
- Strategic value lies in enforcement, licensing, and extending protection via new filings before expiration.
FAQs
Q1: What is the primary active ingredient covered by Patent 7,608,282?
It covers formulations using a selective serotonin reuptake inhibitor, such as escitalopram.
Q2: Can the patent be challenged before expiry?
Yes. Challenges based on prior art, obviousness, or novelty can be filed through patent litigation or administrative proceedings.
Q3: How does the patent impact generic drug entry?
It prevents generic entry until 2026 unless invalidated or licensed otherwise.
Q4: Are there related patents that extend the patent’s scope?
Yes. Several patents cover formulations, methods of use, or delivery methods aligned with the original patent.
Q5: What market segments does this patent influence?
It affects psychiatric treatment markets, particularly depression and anxiety medications, and the pharmaceutical formulations sector.
References
- U.S. Patent 7,608,282. (2009).
- Patent landscape reports from FDA and EPO referencing related drug patent families.
- Legal case filings involving patent litigation for drugs with similar formulations.
- WHO, "Guidelines on the conduct of clinical trials for medicines," 2018.
- Market analysis reports from IQVIA on antidepressant drug patents.
[1] U.S. Patent and Trademark Office. (2009). Patent No. 7,608,282.
[2] European Patent Office. (2023). Patent family documents and related filings.
[3] Court records and legal databases on patent disputes involving this patent.
More… ↓
⤷ Start Trial
|
